Clinical Commissioning Policy Stereotactic ablative radiotherapy (SABR) for the treatment of localised prostate cancer (adults) [2106]
Posted 18th Jun 2026
Stereotactic ablative radiotherapy (SABR) is recommended to be available as a routine commissioning treatment option for adults with low and intermediate risk1 localised prostate cancer who do not require androgen deprivation therapy (ADT) as an alternative to moderately hypo fractionated external beam radiotherapy (EBRT) within the criteria set out
in this document.
The policy is restricted to adults (≥18 years old) as there is insufficient evidence to confirm safety in those age groups not included in the policy.
